Pragmatica-Lung Study opens for patient enrollment
Briefly

The National Cancer Institute, part of the National Institutes of Health (NIH), has helped launch a phase 3 randomized clinical trial ( NCT05633602) of a two-drug combination to treat patients with advanced non-small cell lung cancer (NSCLC).Called the Pragmatica-Lung Study (or S2302), this is one of the first NCI-supported clinical trials to use a trial design that removes many of the barriers that prevent people from joining clinical trials.
Read at National Cancer Institute
[
add
]
[
|
|
]